Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Keeping Track: Merck's Winning Week; Novel Agents Submitted By GSK, Melinta, Portola

Oct 30 2016

• By Bridget Silverman

Related Content

Will Portola’s Betrixaban Data Pass Muster With FDA?

Mar 24 2016

Keeping Track: New Drugs For Glaucoma, Sickle Cell Submitted; IDegLira, Brineura Reviews Extended; Keytruda Advances In First-Line NSCLC

Sep 09 2016

Keeping Track: New Year, New Submissions Roll In To FDA

Jan 11 2016

Portola Seeks Narrower Label For AndexXa Antidote After FDA Rebuff

Aug 19 2016

Melinta reports Phase III success for antibiotic

Jan 09 2015

Merck & Co Expands C Diff Franchise With US Zinplava Approval

Oct 24 2016

GSK Files Blockbuster Hopeful Shingrix With FDA

Oct 24 2016

Merck Says PD-L1 Testing Already On The Rise, Setting Stage For First-Line Launch

Oct 25 2016

Sanofi Working To Resolve GMP Issues That Derailed Sarilumab Approval

Oct 29 2016

FDA Continues To Speed PD-1/L1 Drugs To Market

Oct 25 2016

Merck’s C. Diff Drug Zinplava Clears FDA With Heart Failure Warning

Oct 26 2016

GSK Shingles Vaccine Adds Evidence It Can Outperform Merck’s Zostavax

Sep 15 2016

Related Companies

Merck & Co., Inc.

GSK plc

Melinta Therapeutics, Inc.

Portola Pharmaceuticals, Inc.

Adamas Pharmaceuticals, Inc.

Biogen, Inc.

Aerie Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.

Sanofi

Bristol Myers Squibb Company

Additional Topics

United States Approvals Review Pathway BioPharmaceutical

More from Approvals

More from Product Reviews

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window